Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
Bright Mind Biosciences shares surge on positive epilepsy drug trial results
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% Higher – Here’s What Happened
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of “Buy” by Brokerages
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet
Why Bright Minds Biosciences Stock Topped the Market on Monday
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?
STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
Monster insider trading alert for this penny stock that rallied $3,700% in a week
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Why did this penny stock skyrocket 1,500% in a day
Bright Minds Biosciences Stock Surges Almost 1,500%
Canadian psychedelics company Bright Minds shares rise 1,446% in one day
Bright Minds is Unaware of Any Material Changes
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)